Royalty Pharma RPRX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $2.38B+5.1% | $2.26B-3.9% | $2.35B+5.2% | $2.24B-2.3% | ||
| $452M+22,500% | $2M-96.2% | $52M-70.6% | $177.11M-11.5% | ||
| $573.48M+142% | $236.67M-5.2% | $249.75M+9.9% | $227.3M+24.3% | ||
| —— | $0— | $0-100% | $615.83M— | ||
| $818.67M-15.7% | $971.13M+10.5% | $879.23M-54.4% | $1.93B+125% | ||
| $1.56B+20.7% | $1.29B-13.4% | $1.49B— | —— | ||
| 65.6%+8.5pp | 57.1%-6.3pp | 63.4%— | —— | ||
| $307.66M+36.4% | $225.51M+20.5% | $187.19M-0.4% | $187.96M+13.1% | ||
| $33.59M-29.0% | $47.34M-34.5% | $72.29M-7.7% | $78.34M+46.3% | ||
| -$234.33M— | —— | $207.94M+370% | -$77M+59.4% | ||
| $29.09M-1.8% | $29.61M+2.5% | $28.88M+422% | -$8.97M+54.0% | ||
| $1.33B-0.4% | $1.33B-21.7% | $1.7B— | —— | ||
| $0— | $0— | $0— | $0— | ||
| $771.95M-10.1% | $858.98M-24.3% | $1.13B— | —— | ||
| 32.5%-5.5pp | 37.9%-10.2pp | 48.2%— | —— | ||
| $1.79-6.8% | $1.92-23.8% | $2.52— | —— | ||
| $1.79-7.3% | $1.93-24.0% | $2.54— | —— | ||
| 2.3B-4.9% | 2.4B-1.5% | 2.4B+7.0% | 2.3B+1.0% | ||
| 1.7B-4.2% | 1.8B+0.2% | 1.8B+2.5% | 1.7B+6.4% | ||
| $93.3M— | $0— | $0— | —— | ||
| —— | —— | $87.14M+361% | -$33.44M+30.4% | ||
| $45.86M-70.4% | $154.91M-32.9% | $230.84M+3,487% | -$6.82M-138% | ||
| —— | —— | $18.82M-51.9% | $39.14M+13.8% | ||
| $33.59M-29.0% | $47.34M-34.5% | $72.29M-7.7% | $78.34M— | ||
| $276.29M+73.1% | $159.57M-5.7% | $169.17M-0.6% | $170.14M+30.4% | ||
| —— | —— | -$2.15B-127% | -$944.86M— | ||
| -$1.61B+39.7% | -$2.68B-29.2% | -$2.07B— | —— | ||
| $2.49B-10.1% | $2.77B-7.3% | $2.99B+39.4% | $2.14B+6.3% | ||
| -$14.35M-839% | -$1.53M+93.0% | -$21.74M-47.3% | -$14.76M-160% | ||
| $1.23B+434% | $229.65M— | —— | —— | ||
| $1.7B-32.2% | $2.51B+18.4% | $2.12B+21.5% | $1.74B-20.5% | ||
| $105.15M+345% | $23.64M-46.1% | $43.88M— | $0-100% | ||
| $21.23M+7.3% | $19.79M+1,274% | $1.44M-99.7% | $542.04M+767% | ||
| -$318.94M-144% | $732.46M— | —— | $904.24M+99.7% | ||
| $1.56B+20.7% | $1.29B-13.4% | $1.49B— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Royalty Pharma's revenue?
- Royalty Pharma (RPRX) generated $2.4B in revenue over the trailing twelve months, up 7.8% year over year.
- Is Royalty Pharma profitable?
- Royalty Pharma reported $827.3M in net income over the trailing twelve months, a 33.9% net margin.
- What is Royalty Pharma's earnings per share?
- Royalty Pharma's diluted EPS over the trailing twelve months is $1.91.
- Where does Royalty Pharma's income statement data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
